Ajanta Pharma Q3 net up 92% at Rs 62 cr

Company posted a net profit of Rs 33 crore for the same period of previous fiscal

Press Trust of India New Delhi
Last Updated : Jan 27 2014 | 3:31 PM IST
Drug firm Ajanta Pharma today posted 91.64% rise in its net profit at Rs 62.42 crore for the third quarter ended December 31, 2013, on account of robust sales in the domestic and emerging markets.

The company had posted a net profit of Rs 32.57 crore for the same period of previous fiscal.

Net sales of the company rose to Rs 292.59 crore for the third quarter, as compared to Rs 225.68 crore in the same period of previous fiscal, Ajanta Pharma Ltd said in a filing to the BSE.

Also Read

"We had a good quarter fuelled by strong business performance in India and emerging markets," Ajanta Pharma Joint Managing Director Rajesh Agrawal said.

During the quarter under review, the company's India revenues stood at Rs 98 crore, up 38% over the corresponding period of last fiscal.

Exports to emerging markets, including African and CIS countries, stood at Rs 195 crore during the quarter, a growth of 26%.

Shares of the company were trading at Rs 937.80 apiece on the BSE in late afternoon trade, up 0.27% from its previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 27 2014 | 3:28 PM IST

Next Story